Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00322517 · ClinicalTrials.gov registry record · Phase 2

Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

A Phase 2 study of Breast Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT00322517 is a Phase 2 study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 90 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00322517, a Phase 2 study of Breast Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer

Conditions Studied

Breast Neoplasms

Interventions

  • DRUG SU014813

Study Locations (20)

Other

  • Pfizer Investigational Site - Hamburg
  • Pfizer Investigational Site - Magdeburg
  • Pfizer Investigational Site - Marburg
  • Pfizer Investigational Site - Chieti Scalo
  • Pfizer Investigational Site - Milan
  • Pfizer Investigational Site - Mirano (VE)
  • Pfizer Investigational Site - Udine
  • Pfizer Investigational Site - Amsterdam
  • Pfizer Investigational Site - Rotterdam
  • Pfizer Investigational Site - Edinburgh

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Pasadena
  • Pfizer Investigational Site - Santa Monica
  • Pfizer Investigational Site - Valancia

Mississippi

  • Pfizer Investigational Site - Corinth
  • Pfizer Investigational Site - Southaven

Tennessee

  • Pfizer Investigational Site - Memphis
  • Pfizer Investigational Site - Memphis

M20 4bx

  • Pfizer Investigational Site - Manchester

Surrey

  • Pfizer Investigational Site - Sutton

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2006-04
Est. Completion 2009-07
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00322517

The ClinicalTrials.gov registry entry for NCT00322517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (84% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SU014813 is the first listed.

NCT00322517 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Mississippi.

Frequently Asked Questions

What is clinical trial NCT00322517 about?

NCT00322517 is a clinical study titled "Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer". To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer

What is the current status of trial NCT00322517?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2006-04. Estimated completion is 2009-07.

What conditions does trial NCT00322517 study?

This clinical trial studies the following conditions: Breast Neoplasms.

What interventions are being tested in trial NCT00322517?

The interventions under investigation include: SU014813 (DRUG).

Who is sponsoring clinical trial NCT00322517?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00322517 being conducted?

This trial has 20 study locations across California, Mississippi, Tennessee, M20 4bx, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.